Manual on the proper use of the 211At-labeled PSMA ligand ([211At]PSMA-5) for clinical trials of targeted alpha therapy (1st edition)

Watabe, Tadashi; Namba, Masao; Yanagida, Sachiko; Nakamura, Yoshihide; Yamada, Takahiro; Tatsuno, Saori; Ri, Aritoshi; Yoshida, Shuhei; Uyama, Kumiko; Kinuya, Seigo; Tomiyama, Noriyuki; Hosono, Makoto

doi:https://doi.org/10.1007/s12149-024-01916-6

Manual on the proper use of the 211At-labeled PSMA ligand ([211At]PSMA-5) for clinical trials of targeted alpha therapy (1st edition)

Watabe, Tadashi; Namba, Masao; Yanagida, Sachiko et al.

Annals of Nuclear Medicine, 2024, 38(5), 329-336

Number of Access:1,259（2025-07-28 20:04 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/95726

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
AnnNuclMed_38_5_329	pdf	None	575 KB	97	2024.05.28

Creative Commons : Attribution

Item Information

Output File Export EndNote Basic Export Mendeley

Title	Manual on the proper use of the 211At-labeled PSMA ligand ([211At]PSMA-5) for clinical trials of targeted alpha therapy (1st edition)
Creator	NRID 1000090648932 1000090648932 ORCID 0000-0001-8658-2395 0000-0001-8658-2395 researchmap permalink twosaka2018 twosaka2018 Scopus Author ID 57421862900 57421862900 CreatorName Watabe, Tadashi
	CreatorName Namba, Masao
	CreatorName Yanagida, Sachiko
	CreatorName Nakamura, Yoshihide
	NRID 1000050618816 1000050618816 CreatorName Yamada, Takahiro
	NRID 1000050881463 1000050881463 CreatorName Tatsuno, Saori
	NRID 1000040930409 1000040930409 CreatorName Ri, Aritoshi
	NRID 1000010632606 1000010632606 CreatorName Yoshida, Shuhei
	CreatorName Uyama, Kumiko
	CreatorName Kinuya, Seigo
	NRID 1000050294070 1000050294070 researchmap permalink 3430 3430 Scopus Author ID 7006024942 7006024942 CreatorName Tomiyama, Noriyuki
	NRID 1000000281303 1000000281303 CreatorName Hosono, Makoto
Subject	Astatine
	Prostate cancer
	Radiation exposure
	Safety management
	Targeted alpha therapy
Description	The version of record of this article, first published in Annals of Nuclear Medicine, is available online at Publisher’s website: https://doi.org/10.1007/s12149-024-01916-6.
Abstract	Recently, an astatine-labeled prostate-specific membrane antigen (PSMA) ligand ([211At]PSMA-5) has been developed for the targeted alpha therapy of patients with prostate cancer. This manual delineates its physicochemical characteristics to assist healthcare professionals in understanding the α-ray-emitting drug of [211At]PSMA-5 when administered to patients. The safety considerations regarding the handling and use of this drug in clinical trials are outlined, based on the proper usage manual of previous studies. The dose limits, as defined by the guidelines of the International Commission on Radiological Protection (ICRP) and the International Atomic Energy Agency (IAEA), are assessed for patients’ caregivers and the general public. According to the calculations provided in this manual, clinical trials involving [211At]PSMA-5 can be safely conducted for these populations even if patients are released after its administration. Moreover, this manual provides comprehensive guidance on the handling of [211At]PSMA-5 for healthcare facilities, and compiles a list of precautionary measures to be distributed among patients and their caregivers. While this manual was created by a research team supported by Ministry of Health, Labour, and Welfare in Japan and approved by Japanese Society of Nuclear Medicine, its applicability extends to healthcare providers in other countries. This manual aims to facilitate conducting clinical trials using [211At]PSMA-5 in patients with prostate cancer.
Publisher	Springer
Source Title	Annals of Nuclear Medicine
Volume (Issue)	38(5)
Page	329-336
Date of Issued	2024-05-01
Language	English
Handle URL	https://hdl.handle.net/11094/95726
PISSN	09147187
eISSN	18646433
Relation.isIdenticalTo	DOI (Publisher Version) https://doi.org/10.1007/s12149-024-01916-6
Access Rights	open access
CopyRight	This article is licensed under a Creative Commons Attribution 4.0 International License.
oaire:version	Version of Record
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCMI Type	Text
DCTERMS.bibliographicCitation	Annals of Nuclear Medicine. 2024, 38(5), p. 329-336
DC.title	Manual on the proper use of the 211At-labeled PSMA ligand ([211At]PSMA-5) for clinical trials of targeted alpha therapy (1st edition)
DC.creator	Watabe, Tadashi
	Namba, Masao
	Yanagida, Sachiko
	Nakamura, Yoshihide
	Yamada, Takahiro
	Tatsuno, Saori
	Ri, Aritoshi
	Yoshida, Shuhei
	Uyama, Kumiko
	Kinuya, Seigo
	Tomiyama, Noriyuki
	Hosono, Makoto
DC.publisher	Springer
DC.language' scheme='DCTERMS.RFC1766	English
DC.type' scheme='DCTERMS.DCMIType	Text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2024-05-01
DC.identifier	https://doi.org/10.1007/s12149-024-01916-6
DC.subject	Astatine
	Prostate cancer
	Radiation exposure
	Safety management
	Targeted alpha therapy
DC.description	The version of record of this article, first published in Annals of Nuclear Medicine, is available online at Publisher’s website: https://doi.org/10.1007/s12149-024-01916-6.
DCTERMS.abstract	Recently, an astatine-labeled prostate-specific membrane antigen (PSMA) ligand ([211At]PSMA-5) has been developed for the targeted alpha therapy of patients with prostate cancer. This manual delineates its physicochemical characteristics to assist healthcare professionals in understanding the α-ray-emitting drug of [211At]PSMA-5 when administered to patients. The safety considerations regarding the handling and use of this drug in clinical trials are outlined, based on the proper usage manual of previous studies. The dose limits, as defined by the guidelines of the International Commission on Radiological Protection (ICRP) and the International Atomic Energy Agency (IAEA), are assessed for patients’ caregivers and the general public. According to the calculations provided in this manual, clinical trials involving [211At]PSMA-5 can be safely conducted for these populations even if patients are released after its administration. Moreover, this manual provides comprehensive guidance on the handling of [211At]PSMA-5 for healthcare facilities, and compiles a list of precautionary measures to be distributed among patients and their caregivers. While this manual was created by a research team supported by Ministry of Health, Labour, and Welfare in Japan and approved by Japanese Society of Nuclear Medicine, its applicability extends to healthcare providers in other countries. This manual aims to facilitate conducting clinical trials using [211At]PSMA-5 in patients with prostate cancer.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	95726
citation_title	Manual on the proper use of the 211At-labeled PSMA ligand ([211At]PSMA-5) for clinical trials of targeted alpha therapy (1st edition)
citation_author	Watabe, Tadashi
	Namba, Masao
	Yanagida, Sachiko
	Nakamura, Yoshihide
	Yamada, Takahiro
	Tatsuno, Saori
	Ri, Aritoshi
	Yoshida, Shuhei
	Uyama, Kumiko
	Kinuya, Seigo
	Tomiyama, Noriyuki
	Hosono, Makoto
citation_publisher	Springer
citation_language	English
citation_date	2024-05-01
citation_journal_title	Annals of Nuclear Medicine
citation_volume	38
citation_issue	5
citation_firstpage	329
citation_lastpage	336
citation_doi	https://doi.org/10.1007/s12149-024-01916-6
citation_public_url	https://hdl.handle.net/11094/95726

Manual on the proper use of the 211At-labeled PSMA ligand ([211At]PSMA-5) for clinical trials of targeted alpha therapy (1st edition)

Link to primary information

Item Information

Show details